K. Matsui

发表

Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer.

Hideji Nakamura, T. Iwasaki, K. Nakagawa, 2005, Oncology reports.

Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.

M. Fukuoka, N. Masuda, S. Kudoh, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin

M. Fukuoka, S. Kudoh, M. Takada, 1995, Japanese journal of cancer research : Gann.

Photodynamic therapy and/or external beam radiation therapy for roentgenologically occult lung cancer

M. Fukuoka, M. Takada, K. Matsui, 1994, Cancer.

Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer

Y. Nishimura, M. Fukuoka, N. Yamamoto, 2006, Cancer Chemotherapy and Pharmacology.

Pleural MALT lymphoma diagnosed on thoracoscopic resection under local anesthesia using an insulation‐tipped diathermic knife

K. Takata, T. Yoshino, Hidekazu Suzuki, 2008, Pathology international.

A new electrocautery pleural biopsy technique using an insulated-tip diathermic knife during semirigid pleuroscopy

T. Miyazawa, M. Ohta, Hidekazu Suzuki, 2008, Surgical Endoscopy.

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer.

M. Fukuoka, N. Masuda, S. Kudoh, 1998, British Journal of Cancer.

Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer.

N. Saijo, Y. Nishiwaki, Y. Ohe, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902.

K. Eguchi, Y. Ichinose, M. Fukuoka, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.

M. Fukuoka, I. Kawase, N. Masuda, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.

K. Mori, N. Saijo, Y. Ichinose, 2012, Lung cancer.

Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.

M. Takada, Y. Iwamoto, K. Nakagawa, 2011, Japanese journal of clinical oncology.

A Phase II Study Directed by a Clinical Pathway for Carboplatin and Weekly Paclitaxel in Previously Untreated Patients with Unresectable Non-Small Cell Lung Cancer

I. Kawase, K. Matsui, F. Imamura, 2010, Chemotherapy.

Long-term Pemetrexed Administration in 22 Patients with Non-small Cell Lung Cancer in a Japanese Phase II Randomized Study

K. Matsui, Y. Nambu, S. Enatsu, 2009 .

Phase I and pharmacologic study of oral (E)-2′-deoxy-2′-(fluoromethylene) cytidine: on a daily × 5-day schedule

M. Fukuoka, S. Kudoh, M. Takada, 1998, Investigational New Drugs.

Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: on a daily x 14-day schedule.

M. Fukuoka, N. Masuda, N. Yamamoto, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

M. Fukuoka, N. Masuda, S. Kudoh, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.

M. Shibuya, Y. Ichinose, Y. Nishiwaki, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnostic Accuracy in Peripheral Lung Cancer Using Flexible Fiberoptic Bronchoscope

M. Fukuoka, M. Takada, K. Matsui, 1981 .

Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation.

N. Masuda, M. Takada, K. Furuse, 1998, British Journal of Cancer.

[Risk of second primary cancer in two-year survivors of small cell lung cancer].

M. Fukuoka, K. Tamura, M. Takada, 1996, Nihon Kyobu Shikkan Gakkai zasshi.

Angled forceps used for transbronchial biopsy in which standard forceps are difficult to manipulate: a comparative study.

I. Kawase, K. Matsui, K. Kawahara, 2006, Chest.

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours

M. Fukuoka, S. Kudoh, N. Yamamoto, 2006, British Journal of Cancer.

Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer.

Y. Hosomi, M. Shibuya, K. Eguchi, 2011, Anticancer research.

[Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib].

Y. Nishiwaki, M. Fukuoka, H. Saka, 2004, Gan to kagaku ryoho. Cancer & chemotherapy.

Non-small cell lung cancer: radiation therapy for locoregional recurrence after complete resection

T. Tada, K. Nakagawa, K. Matsui, 2005, International Journal of Clinical Oncology.

Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer

M. Fukuoka, Y. Nakanishi, M. Takada, 2006, Cancer.

CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.

M. Fukuoka, N. Masuda, S. Kudoh, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

H. Tanii, S. Sakajiri, Ken Kobayashi, 2012, Investigational New Drugs.

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.

Yusuke Nakamura, I. Kawase, A. Yokoyama, 2008, Lung cancer.

Radiotherapy and Systemic Chemotherapy for Brain Metastasis in Small Cell Lung Cancer.

I. Kawase, T. Kozuka, T. Tada, 1997 .

[Systemic chemotherapy for brain metastasis from small cell lung cancer].

M. Fukuoka, M. Takada, K. Nakagawa, 1993, Nihon Kyobu Shikkan Gakkai zasshi.

Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer.

T. Nishida, T. Yamadori, Y. Shima, 2006, Cancer science.

Dose-escalation study of oral etoposide and carboplatin in patients with advanced lung cancer.

M. Fukuoka, K. Kubota, M. Takada, 1996, Japanese journal of clinical oncology.

Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer.

N. Masuda, K. Kubota, M. Takada, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin, Vindesine, and Concomitant Radiation Therapy for Unresectable Non-small Cell Lung Cancer.

M. Fukuoka, M. Takada, T. Nakajima, 1991 .

Combination therapy with bestatin in inoperable lung cancer. A randomized trial.

M. Fukuoka, M. Takada, K. Matsui, 1990, Acta oncologica.

A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.

T. Mukohara, M. Fukuoka, S. Kudoh, 2005, Japanese journal of clinical oncology.

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data

E. Miyaoka, A. Gemma, M. Seike, 2022, JTO clinical and research reports.

Ten Cases of Primary Mediastinal Malignant Germ Cell Tumor.

M. Takada, K. Matsui, N. Masuda, 1995 .

[Studies on the appropriate administration of cisplatin based on pharmacokinetics and toxicity].

M. Fukuoka, M. Takada, S. Kobayashi, 1987, Gan to kagaku ryoho. Cancer & chemotherapy.

Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer.

M. Fukuoka, N. Masuda, S. Kudoh, 1991, Journal of the National Cancer Institute.

Asymptomatic endobronchial metastases of typical carcinoid 15 years after curative resection.

T. Iwasaki, K. Nakagawa, K. Matsui, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer.

M. Fukuoka, N. Masuda, S. Kudoh, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Prognosis of small cell lung cancer with ipsilateral pleural effusion].

N. Masuda, S. Kudoh, M. Takada, 1992, Nihon Kyobu Shikkan Gakkai zasshi.

Mitomycin C, vindesine, and cisplatin in advanced non-small-cell lung cancer : a phase II study

M. Fukuoka, S. Kudoh, M. Takada, 1992 .

Prophylactic Cranial Irradiation Prophylactic Cranial Irradiation for Patients with Limited Disease Small Cell Lung Cancer in Complete Remission

K. Minakuchi, T. Nakajima, K. Matsui, 2011 .

Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy

T. Tada, K. Matsui, M. Hosono, 2005, International Journal of Clinical Oncology.

EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.

M. Fukuoka, S. Kudoh, K. Hirata, 2006, Lung cancer.

Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).

Y. Ichinose, M. Fukuoka, M. Ando, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104).

N. Saijo, Y. Nishiwaki, M. Ando, 2009, Annals of Oncology.

Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II Study

N. Saijo, Y. Nishiwaki, M. Fukuoka, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets.

N. Araki, Ken-ichi Watanabe, W. Koizumi, 2004, Japanese journal of clinical oncology.

Phase II clinical study of photodynamic therapy using mono-L-aspartyl chlorin e6 and diode laser for early superficial squamous cell carcinoma of the lung.

Masaaki Kawahara, Masahiro Fukuoka, Teruomi Miyazawa, 2003, Lung cancer.

Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity

J. Christensen, T. Boggon, B. Halmos, 2008, Oncogene.

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.

M. Fukuoka, S. Kudoh, T. Nitta, 1993, British Journal of Cancer.

Enhanced Antitumor Efficacy of a Combination of CPT‐11, a New Derivative of Camptothecin, and Cisplatin against Human Lung Tumor Xenografts

M. Fukuoka, S. Kudoh, M. Takada, 1993, Japanese journal of cancer research : Gann.

Phase II Study of Sequential Triplet Chemotherapy, Irinotecan and Cisplatin Followed by Amrubicin, in Patients with Extensive-Stage Small Cell Lung Cancer: West Japan Thoracic Oncology Group Study 0301

H. Saka, Y. Iwamoto, S. Oizumi, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer

K. Mori, N. Saijo, Y. Nishiwaki, 2008, British Journal of Cancer.

Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.

N. Saijo, K. Kubota, M. Nishio, 2014, The Lancet. Oncology.

Phase II Study of 3-Week Scheduling of Irinotecan in Combination With Cisplatin in Patients With Advanced Nonsmall-Cell Lung Cancer

S. Kudoh, M. Takada, K. Nakagawa, 2006, American journal of clinical oncology.

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma

M. Fukuoka, K. Matsui, Shunsuke Fujimoto, 2019, Internal medicine.

A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.

M. Fukuoka, N. Masuda, S. Kudoh, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer

M. Fukuoka, K. Kubota, M. Takada, 1997, Cancer Chemotherapy and Pharmacology.

Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.

M. Fukuoka, N. Masuda, S. Kudoh, 1991, Journal of the National Cancer Institute.

Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer

M. Fukuoka, Y. Ohashi, S. Kudoh, 2010, Cancer Chemotherapy and Pharmacology.

Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions

Yukiko Nakamura, I. Kawase, T. Nitta, 2007, International Journal of Clinical Oncology.

Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.

M. Fukuoka, K. Tamura, M. Takada, 1996, British Journal of Cancer.

Telomerase activity in endoscopically visible lung cancer.

I. Kawase, T. Nitta, Y. Takada, 2001, Anticancer research.

Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).

M. Fukuoka, M. Ando, S. Kudoh, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer

M. Fukuoka, K. Kubota, S. Kudoh, 1991, Cancer.

CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.

M. Fukuoka, K. Kubota, S. Kudoh, 1997, British Journal of Cancer.

Carboplatin calculated with Chatelut's formula plus etoposide for elderly patients with small-cell lung cancer.

M. Fukuoka, N. Masuda, T. Nitta, 2001, Internal medicine.

Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer.

M. Fukuoka, S. Kudoh, M. Takada, 2010, Clinical lung cancer.

Phase II study of cisplatin, etoposide and concurrent thoracic radiotherapy (TRT) followed by irinotecan and cisplatin in patients with limited stage small-cell lung cancer (SCLC); updated results of WJTOG9902.

K. Eguchi, Y. Ichinose, S. Kudoh, 2004, Journal of Clinical Oncology.

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer

S. Kudoh, K. Yoshimori, H. Niitani, 2001, British Journal of Cancer.

Mitomycin C, Vindesine, and Cisplatin in Advanced Non‐Small-Cell Lung Cancer A Phase II Study

M. Fukuoka, S. Kudoh, M. Takada, 1992, American journal of clinical oncology.

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer

H. Ohmatsu, R. Kakinuma, N. Saijo, 2004, British Journal of Cancer.

[Restorative effect of muroctasin, MDP-Lys (L 18), on leukopenia caused by anticancer chemotherapy in lung cancer--comparative study by envelope method].

M. Fukuoka, M. Takada, K. Matsui, 1988, Gan to kagaku ryoho. Cancer & chemotherapy.

Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515.

N. Saijo, M. Fukuoka, S. Kudoh, 2007, Lung cancer.

Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).

T. Nakano, K. Mori, N. Saijo, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of high‐dose etoposide combined with cisplatin for treating relapsed small cell lung cancer

M. Fukuoka, S. Kudoh, M. Takada, 1990, Cancer.

Proteomics‐based identification of α‐enolase as a tumor antigen in non‐small lung cancer

Ping He, Tomonori Hirashima, Minoru Fujimoto, 2007 .

Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)

S. Kudoh, T. Nakano, M. Fukuoka, 2004, British Journal of Cancer.

[The significance of CA-50, SLX and ST-439 in lung cancer].

S. Kudoh, M. Takada, K. Matsui, 1991, Nihon Kyobu Shikkan Gakkai zasshi.

Randomized phase II study of cisplatin , irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer ( JCOG 9902-DI )

T. Nakano, N. Saijo, Y. Nishiwaki, 2003 .

Three cases of the nodular pulmonary amyloidosis with a longterm observation.

I. Kawase, Hidekazu Suzuki, K. Matsui, 2006, Internal medicine.

A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903)

Y. Nishimura, T. Mitsudomi, M. Fukuoka, 2012, Cancer.

Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer

I. Kawase, T. Tada, K. Minakuchi, 2006, International Journal of Clinical Oncology.

Combination chemotherapy with or without radiation therapy in small cell lung cancer. An analysis of a 5‐year follow‐up

M. Fukuoka, S. Kudoh, M. Takada, 1990, Cancer.

A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer.

M. Fukuoka, N. Masuda, M. Takada, 1991, Japanese journal of clinical oncology.

P3-148: Evaluation of efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non–small cell lung cancer (NSCLC); integrated analysis of two Japanese phase II studies

N. Saijo, Y. Ichinose, Y. Nishiwaki, 2007 .

Randomized phase III study of docetaxel (D) versus vinorelbine (V) for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group trial (WJTOG9904)

M. Fukuoka, M. Takada, T. Satoh, 2005 .

Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer.

N. Masuda, S. Kudoh, K. Furuse, 2000, Japanese journal of clinical oncology.

Weekly Dose‐Intensive Chemotherapy in Patients with Small‐Cell Lung Cancer: A Pilot Study

M. Fukuoka, S. Kudoh, M. Takada, 1992, American journal of clinical oncology.

Redevelopment of Small‐Cell Lung Cancer Nine Years after the Start of Therapy A Case Report and Review of the Literature

M. Fukuoka, S. Kudoh, M. Takada, 1991, American journal of clinical oncology.

Relapse of stage I small cell lung cancer ten or more years after the start of treatment.

T. Tada, Hidekazu Suzuki, K. Nakagawa, 2006, Japanese journal of clinical oncology.

Standard Classification of Autofluorescence Bronchoscopy Findings

H. Honda, M. Tsuboi, T. Miyazawa, 2007 .

Prognosis of small-cell lung cancer since the introduction of amrubicin

I. Kawase, Hidekazu Suzuki, K. Matsui, 2011, Medical oncology.

Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer.

M. Fukuoka, K. Tamura, I. Okamoto, 2009, European journal of cancer.

Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer.

M. Fukuoka, S. Kudoh, M. Takada, 1995, Japanese journal of clinical oncology.

Determinants of Myelosuppression in the Treatment of Non‐small Cell Lung Cancer with Cisplatin‐containing Chemotherapy

M. Fukuoka, I. Kawase, K. Kubota, 1996, Japanese journal of cancer research : Gann.

Three-year disease-free survivors of small cell lung cancer treated with combination chemotherapy with or without chest irradiation.

M. Fukuoka, N. Masuda, M. Takada, 1989, European journal of cancer & clinical oncology.

Pleural sarcomatoid malignant mesothelioma consisting of histiocytoid cells

T. Kawai, T. Iwasaki, K. Matsui, 2007, Pathology international (Print).

[Phase II studies of a single agent and a cis-platinum-based two-drug combination in patients with non-small cell lung cancer].

M. Fukuoka, M. Takada, K. Furuse, 1988, Gan to kagaku ryoho. Cancer & chemotherapy.

H. Saka, Y. Iwamoto, S. Oizumi, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II study of docetaxel plus cisplatin versus docetaxel plus irinotecan in advanced non-small-cell lung cancer. A West Japan Thoracic Oncology Group Study

M. Fukuoka, N. Yamamoto, K. Matsui, 2000 .